Page last updated: 2024-11-07

hrp 102

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

estradiol, norethindrone drug combination: combination of estradiol & norethindrone acetate; [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID115350
MeSH IDM0232740

Synonyms (8)

Synonym
mesigyna
estradiol, norethindrone drug combination
99897-30-0
hrp 102
19-norpregn-4-en-20-yn-3-one, 17-((1-oxoheptyl)oxy)-, (17alpha)-, mixt. with (17beta)-3-hydroxyestra-1,3,5(10)-trien-17-yl pentanoate
3-hydroxyestra-1(10),2,4-trien-17-yl pentanoate--3-oxo-19-norpregn-4-en-20-yn-17-yl heptanoate (1/1)
DTXSID60912418
[(8r,9s,10r,13s,14s,17r)-17-ethynyl-13-methyl-3-oxo-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] heptanoate;[(8r,9s,13s,14s,17s)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] pentanoate

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"E2 concentrations, bleeding pattern, exploratory bone metabolism biomarkers, and adverse events."( Gonadotropin-Releasing Hormone Receptor Antagonist Mono- and Combination Therapy With Estradiol/Norethindrone Acetate Add-Back: Pharmacodynamics and Safety of OBE2109.
Fawkes, N; Gotteland, JP; Loumaye, E; Marchand, L; Pohl, O, 2018
)
0.48
" Add-back therapy may be required to prevent adverse effects on bone in women treated with the 200-mg dose (at 100 mg in some women)."( Gonadotropin-Releasing Hormone Receptor Antagonist Mono- and Combination Therapy With Estradiol/Norethindrone Acetate Add-Back: Pharmacodynamics and Safety of OBE2109.
Fawkes, N; Gotteland, JP; Loumaye, E; Marchand, L; Pohl, O, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (6.06)18.7374
1990's15 (45.45)18.2507
2000's8 (24.24)29.6817
2010's7 (21.21)24.3611
2020's1 (3.03)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.41 (24.57)
Research Supply Index3.97 (2.92)
Research Growth Index5.38 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials19 (57.58%)5.53%
Reviews7 (21.21%)6.00%
Case Studies1 (3.03%)4.05%
Observational0 (0.00%)0.25%
Other6 (18.18%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]